Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1998-04-02
2000-09-12
Stucker, Jeffrey
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435 71, 435 792, 435 794, 435 795, 436518, 436532, 530323, 530326, 530327, 530328, 530329, 530356, 5303881, 5303891, G01N 3353
Patent
active
06117646&
ABSTRACT:
Type I collagen degradation products are assayed in a body fluid by conducting a competition immunoassay in which sample molecules compete with a peptide or isomerized peptide in binding to an immunological binding partner for the peptide or isomerized peptide respectively, wherein the peptide or isomerized peptide comprises the amino acids AHDGGR optionally extended at the N-terminal end with one or more amino acids that do not form a contiguous sequence with AHDGGR in type 1 collagen, and wherein D represents aspartic acid or .beta.-aspartic acid. The peptide C(X).sub.n AHDGGR, where X is any amino acid and n is preferably from 4 to 6 is provided for use in such assays and in diagnostic assay kits.
REFERENCES:
patent: 3600132 (1971-08-01), Goverde
patent: 4312853 (1982-01-01), Timpl
patent: 4504587 (1985-03-01), Timpl et al.
patent: 4628027 (1986-12-01), Gay
patent: 4778768 (1988-10-01), Heinegard et al.
patent: 4973666 (1990-11-01), Eyre
patent: 5001225 (1991-03-01), Taylor
patent: 5140103 (1992-08-01), Eyre
patent: 5300434 (1994-04-01), Eyre
patent: 5320970 (1994-06-01), Eyre
patent: 5455179 (1995-10-01), Eyre
patent: 5472884 (1995-12-01), Eyre
patent: 5473052 (1995-12-01), Eyre
patent: 5532169 (1996-07-01), Eyre
patent: 5576189 (1996-11-01), Eyre
patent: 5607862 (1997-03-01), Eyre
International Search Report dated Feb. 15, 1995 of Int'l Appl. No. PCT/DK94/00348.
Ala-Kokko et al., 1989, "Structure of cDNA clones coding for the entire prepro.alpha.1(III) chain of human type III procollagen", Biochem. J. 260:509-516.
Ala-Kokko et al., 1990, "Single base mutation in the type II procollagen gene (COL2A1) as a cause of primary osteoarthritis associated with a mild chondrodysplasia", Proc. Natl. Acad. Sci. 87:6565-6568.
Baldwin et al., 1989, "Structure of CDNA clones coding for human type II procollagen", Biochem. J. 262:521-528.
Beardsworth et al., 1990, "Changes with age in the urinary excretion of lysyl- and hydroxylysylpyridinoline, two new markers of bone collagen turnover", J. Bone Miner. Res. 5:671-676.
Bernard et al., 1983, "Nucleotide Sequences of Complementary Deoxyribonucleic Acids for the Pro.alpha.1 Chain of Human Type I Procollagen. Statistical Evaluation of Structures That Are Conserved during Evolution", Biochemistry 22:5213-5223.
Black et al., 1988, "Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography", Ana. Biochem. 169:197-203.
Black et al., 1989, "Urinary excretion of the hydroxypyridinium cross links of collagen in patients with rheumatoid arthritis", Annals of the Rheumatic Diseases 48:641-644.
Bonde et al., 1994, "Immunoassay for Quantifying Type 1 Collagen Degradation Products in Urine Evaluated", Clin. Chem. 40(11):2022-2025.
Bonde et al., 1995, "Measurement of Bone Degradation Products in Serum Using Antibodies Reactive with an 8 Amino Acid Sequence of the C-Telopeptides of Type I Collagen", J. of Bone and Min. Res. 10:1-Abstract S481.
Brennan et al., 1993, "Spontaneous degradation of polypeptides at aspartyl and asparaginyl residues: Effects of the solvent dielectric", Protein Science 2:331-338.
Capecchi et al., "Critical examination of a method for the analysis of .alpha. and .omega. linkages in peptides containing aspartic acid and glutamic acid", J. Org. Chem. 48:2014-2021.
Christiansen et al., "Prediction of future fracture risk", eds, Proceedings 1993. Fourth International Symposium on Osteoporosis, Hong Kong. Osteopress Aps 1993; pp. 52-54.
Chu et al., 1984, "Human pro.alpha.1(I) collagen gene structure reveals evolutionary conservation of a pattern of itrons and exons", Nature 310:337-340.
Click et al., 1970, "Isolation and Characterization of the Cyanogen Bromide Peptides from the .alpha.1 and .alpha.2 Chains of Human Skin Collagen", Biochemistry 9:4699-4706.
de Wet et al., 1987, "Organization of the Human Pro-.alpha.2(I) Collagen Gene", J. Biol. Chem. 262:16032-16036.
del Pozo et al., 1986, "Binding of 1-anilinoaphthalene-8-sulfonic acid to type I collagen" Int. J. Pept. Protein Res. 28:173-178.
Delmas et al., 1986, "Serum Bone GLA-Protein in Growth Hormone Deficient Children", J. Bone Min. Res. 1:333-337.
Delmas, P.D., 1990, "Biochemical markers of bone turnover for the clinical assessment of metabolic bone disease", Metabolic Bone Dis. 19:1-18.
Dickson et al., 1993, "Pyridinolines and Cross-linked Type I Collagen N-telopeptides as Markers of Bone Metastases in Breast Cancer", 15.sup.th Annual Mtg of the Amer. Soc. for Bone & Min. Res., Tampa, Fl., Sep., 8:S288, Abstr. 686.
Dodge et al., 1989, "Immunohistochemical Detection and Immunochemical Analysis of Type II Collagen Degradation in Human Normal, Rheumatoid, and Osteoarthritic Articular Cartilages and in Explants of Bovine Articular Cartilage Cultured with Interleukin 1", J. Clin. Invest. 83:647-661.
Eyre et al., 1984, "Quantitation of Hydroxypyridinium Crosslinks in Collagen by High-Performance Liquid Chromatography", Analytical Biochemisty 137:380.
Eyre et al., 1988, "Identification of urinary peptides derived from cross-linking sites in bone collagen in Paget's disease", J. of Bone & Mineral Res 3:S210, Abstr.565.
Eyre, D.R., 1984, "Cross-linking in Collagen and Elastin", Ann. Rev. Biochem. 53:717-748.
Eyre, D.R., 1994, "New Molecular Markers of Bone Metabolism", Therapeutic Research (Symposium) 15(2):532-535.
Fledelius et al., 1994, "Estimation of Bone Resorption Using Monoclonal Antibodies to Human Type I Collagen", Am. Soc. of Bone and Min. Res., Abst. C344.
Fujimoto, D., 1980, "Evidence for natural existence of pyridinoline crosslink in collagen", Biochem. & Biophys. Res. Comm. 93:948-953.
Fujimoto et al., 1983, "Analysis of pyridinoline, a cross-linking compound of collagne fibers, in human urine", J. Biochem. 94:1133-1136.
Furthmayr, H., 1982, "Immunization procedures, isolation by affinity chromatography, and serological and immunochemical characterization of collagen specific antibodies", Immunochemistry of the extracellular matrix, H. Furthmayr (ed.), CRC Press, Vol. 1, Chap. 11, pp. 143-178.
Galletti et al., 1995, "Protein damage and methylation-mediated repair in the erythrocyte" Biochem. J. 306:313-325.
Garnero et al., "Assessment of Bone Resportion with a New Marker of Collagen Degradation in Patients with Metabolic Bone Disease", J. Clin. Endo. and Met. 79(3):780-785.
Garnero et al., 1994, "Different Effects of Bisphosphonate and Estrogen therapy on the Excretion of Free and Peptide-Bound Crosslinks", Amer. Soc. of Bone and Min. Res., Abst. 134.
Gertz et al., 1994, "Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine", J. of Bone & Min. Res. 9(2):135-142.
Gunja-Smith et al, 1981 "Collagen cross-linking compounds in human urine", Biochem. J. 197:759-762.
Hanson et al., 1992, "A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine", J. of Bone & Min. Res. 7:1251-1258.
Hassager et al., 1994, "The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: The effect of nandrolone decanoate and hormone replacement therapy", Calcif. Tissue Int. 54:30-33.
Henkel et al., 1987, "Characterisation of a type-I collagen trimeric cross-linked peptide from calf aorta and it cross-linked structure", Eur. J. Biochem. 165:427-436.
Ishikawa, E., 1983, "Enzyme-Labeling of Antibodies and their Fragments for Enzyme Immunoassay and Immunohistochemical Staining", Journal of Immunoassay 4(3):209-327.
Janeczko et al., 1989, "Nucleotide and amino acid sequences of the entire human .alpha.1 (III) collagen", Nucl. Acids Res. 17:6742.
Kiviriko, K.I., 1979, "Urinary Excretion of Hydroxyproline in Health and Disease", Int. Rev. Connect. Tissue Res. 5:93-163.
Krane et al., 1981, "Organic Matrix Defects in Metabolic and Related Bone Diseases", Develop. Biochem. 22:185-194.
Kruger-Franke, 1991, "Pyridinoline-containing collagen degradation products in the urine of patients with osteoarthrosis of the hip joint", Z. Rheumato
Bonde Martin
Qvist Per
Osteometer Biotech A/S
Stucker Jeffrey
LandOfFree
Assaying protein fragments in body fluids does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Assaying protein fragments in body fluids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assaying protein fragments in body fluids will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-94559